Literature DB >> 22428664

Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells.

Stefania Merighi1, Stefania Gessi, Katia Varani, Debora Fazzi, Prisco Mirandola, Pier Andrea Borea.   

Abstract

BACKGROUND AND
PURPOSE: Among several pharmacological properties, analgesia is the most common feature shared by either opioid or cannabinoid systems. Cannabinoids and opioids are distinct drug classes that have been historically used separately or in combination to treat different pain states. In the present study, we characterized the signal transduction pathways mediated by cannabinoid CB(2) and µ-opioid receptors in quiescent and LPS-stimulated murine microglial cells. EXPERIMENTAL APPROACH: We examined the effects of µ-opioid and CB(2) receptor stimulation on phosphorylation of MAPKs and Akt and on IL-1β, TNF-α, IL-6 and NO production in primary mouse microglial cells. KEY
RESULTS: Morphine enhanced release of the proinflammatory cytokines, IL-1β, TNF-α, IL-6, and of NO via µ-opioid receptor in activated microglial cells. In contrast, CB(2) receptor stimulation attenuated morphine-induced microglial proinflammatory mediator increases, interfering with morphine action by acting on the Akt-ERK1/2 signalling pathway. CONCLUSIONS AND IMPLICATIONS: Because glial activation opposes opioid analgesia and enhances opioid tolerance and dependence, we suggest that CB(2) receptors, by inhibiting microglial activity, may be potential targets to increase clinical efficacy of opioids.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22428664      PMCID: PMC3448900          DOI: 10.1111/j.1476-5381.2012.01948.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  79 in total

1.  CB2 cannabinoid receptor-mediated peripheral antinociception.

Authors:  T P Malan; M M Ibrahim; H Deng; Q Liu; H P Mata; T Vanderah; F Porreca; A Makriyannis
Journal:  Pain       Date:  2001-09       Impact factor: 6.961

2.  Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats.

Authors:  Vasudeva Raghavendra; Flobert Y Tanga; Joyce A DeLeo
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

Review 3.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 4.  Cellular mechanisms underlying the interaction between cannabinoid and opioid system.

Authors:  D Parolaro; T Rubino; D Viganò; P Massi; C Guidali; N Realini
Journal:  Curr Drug Targets       Date:  2010-04       Impact factor: 3.465

5.  The involvement of glial cells in the development of morphine tolerance.

Authors:  P Song; Z Q Zhao
Journal:  Neurosci Res       Date:  2001-03       Impact factor: 3.304

Review 6.  Evidence for novel cannabinoid receptors.

Authors:  Malcolm Begg; Pál Pacher; Sándor Bátkai; Douglas Osei-Hyiaman; László Offertáler; Fong Ming Mo; Jie Liu; George Kunos
Journal:  Pharmacol Ther       Date:  2005-01-11       Impact factor: 12.310

7.  A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro.

Authors:  Marzena Lazarczyk; Ewa Matyja; Andrzej W Lipkowski
Journal:  Peptides       Date:  2010-05-24       Impact factor: 3.750

8.  A differential role for the mitogen-activated protein kinases in lipopolysaccharide signaling: the MEK/ERK pathway is not essential for nitric oxide and interleukin 1beta production.

Authors:  Jyoti J Watters; Julie A Sommer; Zachary A Pfeiffer; Usha Prabhu; Alma N Guerra; Paul J Bertics
Journal:  J Biol Chem       Date:  2002-01-10       Impact factor: 5.157

Review 9.  Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.

Authors:  Nephi Stella
Journal:  Glia       Date:  2010-07       Impact factor: 7.452

10.  Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.

Authors:  Stefania Merighi; Annalisa Benini; Prisco Mirandola; Stefania Gessi; Katia Varani; Carolina Simioni; Edward Leung; Stephen Maclennan; Pier Giovanni Baraldi; Pier Andrea Borea
Journal:  Mol Pharmacol       Date:  2007-05-08       Impact factor: 4.436

View more
  17 in total

1.  Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Authors:  Ai-Ling Li; Xiaoyan Lin; Amey S Dhopeshwarkar; Ana Carla Thomaz; Lawrence M Carey; Yingpeng Liu; Spyros P Nikas; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2018-11-30       Impact factor: 4.436

Review 2.  An overview of the cannabinoid type 2 receptor system and its therapeutic potential.

Authors:  Bihua Bie; Jiang Wu; Joseph F Foss; Mohamed Naguib
Journal:  Curr Opin Anaesthesiol       Date:  2018-08       Impact factor: 2.706

3.  The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.

Authors:  Jenny L Wilkerson; Sudeshna Ghosh; Mohammed Mustafa; Rehab A Abdullah; Micah J Niphakis; Roberto Cabrera; Rafael L Maldonado; Benjamin F Cravatt; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2016-11-25       Impact factor: 5.250

4.  Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

Authors:  Shaness A Grenald; Madison A Young; Yue Wang; Michael H Ossipov; Mohab M Ibrahim; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Neuropharmacology       Date:  2016-12-20       Impact factor: 5.250

Review 5.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

6.  The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons.

Authors:  N Murataeva; K Mackie; A Straiker
Journal:  Pharmacol Res       Date:  2012-08-14       Impact factor: 7.658

7.  The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.

Authors:  Jenny L Wilkerson; Micah J Niphakis; Travis W Grim; Mohammed A Mustafa; Rehab A Abdullah; Justin L Poklis; William L Dewey; Hamid Akbarali; Matthew L Banks; Laura E Wise; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2016-01-20       Impact factor: 4.030

8.  Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence.

Authors:  Xiaoyan Lin; Amey S Dhopeshwarkar; Megan Huibregtse; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2017-11-30       Impact factor: 4.436

9.  The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence.

Authors:  Vishakh Iyer; Richard A Slivicki; Ana C Thomaz; Jonathon D Crystal; Ken Mackie; Andrea G Hohmann
Journal:  Eur J Pharmacol       Date:  2020-09-05       Impact factor: 4.432

10.  Involvement of neuronal TGF-β activated kinase 1 in the development of tolerance to morphine-induced antinociception in rat spinal cord.

Authors:  Hao Xu; Tao Xu; Xiaqing Ma; Wei Jiang
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.